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Introductory note 
 
From the research conducted in the three years of PhD, the following articles, abstract 
and presentations were published in national and international pediatric Neuro-oncology 
congresses: 
 
- FSTL5 expression is a marker of Group C metastatic medulloblastomas. 
Authors: C. Baldi, S. Minasi, F. Gianno, M. Massimino, F. Giangaspero, and F.R. 
Buttarelli. 
Abstract - Poster "British Neuro Oncology Society (BNOS) Conference Report 2014" 
Liverpool; P-43. 
 
- Distribution and prognostic impact of molecular subgroups in a homogeneously 
treated series of metastatic medulloblastoma. 
Authors: M. Massimino, F.R. Buttarelli, C. Baldi, S. Minasi, M. Antonelli, F. 
Giangaspero. 
Abstract - Poster 47th Congress of International Society of Pediatric Oncology (SIOP) 
2015, Cape Town; P-158.  
 
- Distribution and prognostic impact of molecular subgroups in a homogeneously 
treated series of metastatic medulloblastoma. 
Authors: F.R. Buttarelli, F. Giangaspero, S. Minasi, M. Antonelli, M. Massimino.  
Abstract - Poster "International Symposium on Pediatric Neuro-Oncology (ISPNO 
2016)" Leeds; MB-76. 
 
- Brafv600e and Ctbn1 Mutational Study in Rathke's Cleft Cysts. 
Authors: Antonelli M, Badiali M, Moi L, Arcella A, Buttarelli FR, S. Minasi and 
Giangaspero F. 
Article published on September 05, 2016; J Clin Exp Pathol 2016, 6:5; doi: 
10.4172/2161-0681.1000291. 
 
Furthermore, during the three years of PhD, I was declared the winner of the following 
research fellowship on the project:  
 
- Study of tumor biomarkers for molecular characterization of pediatric 
medulloblastomas.  
"Sapienza University of Rome", Department of Paediatrics and Child Neurology; 
Scientific Director Professor Anna Clerico. 
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INTRODUCTION 
 
 
Pediatric brain tumors  
 
Central Nervous System (SNC) tumors are the principle cause of death for children and 
adolescents. Central Brain Tumor Registry of the United States (CBTRUS) data 
reported that most of pediatric brain tumors are situated in hemisphere (18%), followed 
by cerebellum (15%), brainstem (11%) e ventricles (6%). Carcinogenesis is a multistep 
process in which epigenetic changes and genetic alterations accumulate in the genomes 
of cancer cells. Few molecular hallmarks and signaling abnormalities have been 
identified as drivers for most aggressive tumors. 
Pediatric brain tumors (PBT), comprising multiple separate pathological entities, are the 
most common group of solid cancers in children (Mangerel et al., 2014). Recent 
discoveries using next-generation genomic platforms have uncovered substantial 
molecular heterogeneity even amongst PBTs with the same histological classification, 
like subgroups of medulloblastoma (De Braganca et al., 2013; Kool et al., 2008), glioma 
(Kim JH et al., 2013), and ependymoma (Mack et al., 2014; Parker et al., 2014).  
Malignant gliomas represent 55% of CNS tumors in childhood and the 71% of 
malignant CNS tumors in adults; pediatric high-grade gliomas (pHGG) are 
histologically similar to the adult counterpart, but show some differences at molecular 
level. 
Although curative therapy options are still absent and long-term survivors are an 
exception in adults as well as in children (Reifenberger et al., 2014), infants (< 3 years 
of age) with high-grade gliomas (iHGG) appear to have a better clinical outcome 
(Antonelli et el., 2010; Batra et al. 2014, Karremann et al., 2013; Merchant et al., 2010). 
Pediatric high grade gliomas (pHGG) are classified and graded according to histological 
criteria (oligodendroglioma, oligoastrocytoma, astrocytoma, and glioblastoma; grade II 
to IV). Although histopathologic classification is well established and is the basis of the 
World Health Organization (WHO) classification of CNS tumors (Louis et al., 2007), it 
suffers from high intra- and inter- variability. Recent molecular characterization studies 
have related genetic, gene expression, and DNA methylation signatures with prognosis 
(Noushmehr et al., 2010; Sturm et al., 2012).   
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In cerebellum medulloblastomas arise from the external granular layer, correspond to 
grade IV WHO, and often occur with leptomeningeal dissemination at the onset. 
Although medulloblastoma is the most common malignant brain tumor of childhood, 
the identity of molecules that are useful therapeutic targets in medulloblastoma is 
largely unknown due to the lack of fundamental knowledge on the molecular 
pathogenesis of the disease. Within the last few years it became clear that 
medulloblastoma is a very heterogeneous disease comprising at least four molecular 
subgroups (WNT, SHH, Group 3 and Group 4), associated with different outcomes 
(Northcott et al., 2011; Taylor et al., 2012; Ramaswamy et al., 2016).  
 
 
  
7 
 
Molecular subgrouping of medulloblastomas 
 
Medulloblastoma (MDB), the most frequent malignant brain tumor in children, is a 
clinically and biologically heterogeneous disease. The prognostic system based on 
clinical parameters such as patient age, extent of surgical resection, metastatic spread 
and histopathological variants is commonly used in clinical practice (Ellison et al., 
2010; Korshunov et al., 2012).  Approximately 10% to 15% of patients die from disease 
within 2 years after diagnosis, whereas approximately 60% of patients can now be cured 
(Massimino et al., 2012; Ramaswamy et al., 2016; Van Bueren et al., 2016). Recent 
studies of gene expression profiles revealed distinct molecular subgroups with different 
biological features (Kool et al., 2012; Ramaswamy et al., 2016; Taylor et al., 2012); the 
current consensus predicts the existence of four subgroups: SHH, WNT, group 3 and 
group 4, associated with different outcome of patients (Fattet et., 2009; Kool et al., 
2008; Northcott et al., 2011; Northcott et al., 2012a; Northcott et al., 2012b; 
Ramaswamy et al., 2016; Remke et al., 2011b; Robinson et al 2012; Taylor et al., 2012). 
The group WNT is associated with nuclear translocation of β-catenin, mutations in exon 
3 of CTNNB1 and monosomy of chromosome 6. The outcome is excellent, with a 
survival rate over 90% (Ellison et al., 2011b; Ellison et al., 2005; Fattet et al., 2009; 
Ramaswamy et al., 2016). The SHH group is associated with somatic mutations of the 
genes SMO, PTCH and SUFU, triple immuno-positivity for GAB1, YAP1 and Filamin 
A, TP53 mutations, amplification of MYCN and GLI2, deletion of chromosome 9q and 
10q and duplication of chromosome 3q (Ellison et al., 2011b; Korshunov et al., 2012; 
Ramaswamy et al., 2016; Taylor et al., 2012). Tumors in group 3 are characterized by 
the loss of chromosomes 10q and 5q, duplication of chromosome 1q, NPR3 and OTX2 
high expression and recurrent MYC amplification (Ramaswamy et al., 2016; Robinson 
et al., 2012; Taylor et al., 2012). Within group 4 MDB, tumors are characterized by 
MYCN amplification, immuno-positivity for KCNA1 and OTX2, loss of the X 
chromosome in female subjects and isochromosome 17q, also shared by the group 3 
(Ellison et al., 2011a; Ellison et al., 2011b; Ellison et al., 2005; Korshunov et al., 2012; 
Ramaswamy et al., 2016; Robinson et al., 2012; Taylor et al., 2012); for group 3 and 4, 
there is no evidence of any alteration in a specific pathway. 
Medulloblastomas can disseminate through the cerebrospinal fluid in the 
leptomeningeal space to coat the brain and spinal cord. Metastasis arise from a restricted 
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sub-clone of the primary tumor, in which genetic events make neoplastic cells able to 
metastasize, through a process of clonal selection (Wu et al., 2012).  
Across several biologically informed cohorts of pediatric MDB, metastatic 
dissemination was considered as a marker of poor prognosis (Lannering et al., 2012). 
Various studies indicated molecular subgrouping correlation with prognostic 
stratification of pediatric patients, but some survival information remain unknown for 
MDB with metastatic spread at diagnosis. Recent study confirmed the relevance of 
subgroup status and biologic parameters (WNT/MYCC/MYCN status) in a 
homogeneous prospective trial population of 121 metastatic MDB (Van Bueren et al., 
2016); data evidenced a favourable risk group (metastatic WNT-patients), a high-risk 
group (group 3 with MYC or MYCN amplification), and a large group of intermediate-
risk patients (Van Bueren et al., 2016).  
Risk groups were defined based on current survival rates: low risk (>90% survival), 
standard risk (75-90% survival), high risk (75-50% survival) and very high risk (<50% 
survival) (Ramaswamy et al., 2016). Group 3 are frequently metastatic (>50%) and 
overall outcome is worse compared to the other subgroups (Ramaswamy et al., 2013); 
group 3 cases with metastasis at the onset have been identified as being very high risk 
(Ramaswamy et al., 2016; Shih et al., 2014; Van Bueren et al., 2016). Approximately 
30% of group 4 medulloblastomas are metastatic at diagnosis; metastatic cases of group 
SHH and group 4 were considered high risk patients (Fig. 1) (Ramaswamy et al., 2013; 
Ramaswamy et al., 2016; Van Bueren et al., 2016). The low incidence of metastatic 
dissemination in WNT (<5%) medulloblastomas precludes any recommendation, and 
their risk stratification remains indeterminate (Ramaswamy et al., 2016). However, 
recent work showed the prognostic role of WNT activation in a cohort of patients with 
metastatic disease and highlighted that four patients with metastatic WNT-activated 
medulloblastoma survived without relapse, indicating that WNT metastatic MDB may 
be treated successfully by less intensive treatment regimens (standard risk protocol) 
because they might be overtreated by current high-risk regimens (Van Bueren et al., 
2016).   
In conclusion, only one published work (Van Bueren et al., 2016) analyzed 
medulloblastomas with metastasis at the onset separately from primary 
medulloblastoma; in fact, the percentage of metastatic cases in most of the studies did 
not exceed 30% and were not analyzed independently from the non-metastatic 
counterpart. We evaluated molecular biomarkers and subgroups in a large cohort of 
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pediatric patients with leptomeningeal dissemination at the onset, in order to define risk 
classes and to elucidate relevant aspects of the metastatic disease.  
 
 
 
 
 
Fig. 1: Current proposed risk stratification by Ramaswamy and colleagues for childhood 
medulloblastoma with metastasis at diagnosis. LR low risk, SR standard risk, HR high risk, VHR very 
high risk (from: Ramaswamy et al., 2016). 
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Follistatin-like 5  
 
Follistatin-like 5 (FSTL5), a member of the follistatin family of genes, encodes a 
secretory glycoprotein. Previous study revealed that it might play a role in MDB; 
FSTL5 was over-expressed in group 3 and high-risk group 4 tumors and was 
significantly associated with reduced progression-free and overall survival across all 
disease variants; a lower FSTL5 expression characterized SHH and WNT group and 
correlated with a longer outcome (Fig. 2) (Gilbertson et al., 2011; Northcott et al., 
2012a; Northcott et al., 2012b; Remke et al., 2011a). The current findings conclude that 
FSTL5 can be a reliable prognostic marker for MDB.  
Recent study examined FSTL5 expression pattern in 117 hepatocellular carcinoma 
(HCC) tissue samples. The results of immune-histochemical staining and further 
clinicopathological analysis showed that FSTL5 expression level is closely correlated 
with tumor size, TNM stage, local infiltration and patient prognosis (Zhang et al., 2015). 
However, its clinical significances, biological functions and molecular mechanisms in 
cancer development are poorly understood.  
FSTL5 gene encode a calcium ion (Ca2+) binding domain; calcium-binding proteins 
participate in calcium cell signalling pathways by binding to Ca2+. The dysregulation of 
Ca2+ homeostasis in cancer cells has been suggested as an important event in driving the 
expression of the malignant phenotypes, such as proliferation, migration, invasion, neo-
angiogenesis and metastasis (Yang et al., 2010; Yih-Fung et al., 2013). Recent 
publication showed that elevated extra-cellular Ca2+ activated the calcium-sensing 
receptor (CaSR), a widely expressed homodimeric G-protein involved in promoting 
migration, brain development, stem-cell engraftment, wound healing, tumor growth and 
metastasis (Tharmalingam et al., 2016). 
On the basis of the knowledge about pathways involved in the processes of invasion, 
metastasis and cell survival, we evaluated the FSTL5 gene expression levels and 
prognostic value in our cohort of metastatic medulloblastomas at the onset. 
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Fig. 2: Expression of follistatin-like 5 (FSTL5) transcripts derived from transcriptome analysis of primary 
medulloblastoma, grouped according to molecular disease variants (a).  Kaplan-Meier plot of estimated 
OS time distributions according to FSTL5 mRNA (b) (from: Remke et al., 2011a).  
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Control of Telomeres lengthening and senescence escape 
 
Cell immortalization has been considered for a long time as a classic hallmark of cancer 
cells. Telomeres are nucleoprotein complexes at the ends of eukaryotic chromosomes 
consisting of several repeats of the DNA sequence 5′-TTAGGG-3′, and contain no gene-
coding information (Oganasian et al., 2009). The main function of telomeres is to 
preserve chromosome integrity and genome stability by preventing loss of genetic 
information which occurs due to lagging-strand shortening during DNA replication 
(Rubtsova et al., 2012). At each cell division, the telomeric DNA is diminished and 
telomeres become progressively shorter; eventually, this loss leads to a stop in cell 
division that forces cell senescence or cell death. Cells which are unable to maintain 
their telomeres undergo senescence and apoptosis; therefore, to maintain replicative 
ability, a telomere maintenance pathway must be activated by cancer cells (Ceccarelli et 
al., 2016; Mangerel et al., 2014). 
Telomere length maintenance is required for tumor self-renewal and is activated 
ubiquitously in most malignant cancers. There are two major pathways that cells use to 
maintain telomere length; they either reactivate telomerase, a ribonucleoprotein 
polymerase which elongates telomeres by adding hexameric 5′-TTAGGG-3′ tandem 
repeats to the chromosomal ends, or take advantage of a non-telomerase-dependent 
mechanism, known as Alternative Lengthening of Telomeres (ALT) (Castelo-Branco et 
al., 2011; Ceccarelli et al., 2016; Cesare et al., 2010; Koelsche et al., 2013; Mangerel et 
al., 2014).  
Telomerase has been found to be critically important for the maintenance of tumor-
initiating cells, which are chemo-resistant cells able to repopulate the tumor and driver 
of recurrence (Marian et al., 2010). Telomeres are maintained in most cancers by 
telomerase reactivation, but a subset of tumors utilize alternative lengthening of 
telomeres to sustain self-renewal capacity (Castelo-Branco et al., 2011; Ceccarelli et al., 
2016).  
The telomerase complex comprises several components, but the telomerase reverse 
transcriptase catalytic subunit (TERT) (Cifuentes-Rojas et al., 2012; Montanaro et al., 
2008; Nandakumar et al., 2013) is the only component necessary to restore the activity 
of the telomerase complex. 
Recently, activating mutations in the TERT promoter were uncovered in melanoma 
(Horn et al., 2013) and other tumors, including several brain tumors (Ceccarelli et al., 
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2016; Koelsche et al., 2013; Mangerel et al., 2014). The TERT gene is located on 
chromosome 5 and includes 16 exons that span a 35-kb region. The core promoter of 
TERT includes 630 base pairs upstream of the start site, was in a GC-rich region and 
contains transcript sites/consensus for transcription elements, indicating a high level of 
regulation by multiple factors at transcriptional and/or post-transcriptional level 
(Cifuentes-Rojas C et al., 2012). 
Hot spot mutations in the promoter region of TERT result in an upregulation of 
telomerase complex activity and thus constitute a relevant mechanism for the 
maintenance of telomere length and the immortalization of tumor cells. Among CNS 
tumors, gliomas are those displaying by far the highest frequency of TERT mutations, 
but these promoter mutations are rarer in pediatric CNS tumors (Ceccarelli et al., 2016; 
Koelsche et al., 2013); in pediatric medulloblastomas, TERT promoter mutations are 
mainly detected in tumors of the group of older patients and are associated with sonic 
hedgehog and WNT mutations (Remke, Ramaswamy et al., 2013). TERT promoter 
mutations are rare in pediatric tumors of the CNS; these findings are consistent with the 
fact that the cells, from which pediatric CNS tumors are thought to originate, still have 
activated telomerase which obviates the need for activation of TERT through promoter 
mutation.  
Within adult gliomas, the percentage of cases with TERT promoter mutations differs 
according to the histopathological type of tumors. TERT promoter mutations are 
detected in most cases of glioblastoma multiforme (GBM), in contrast to astrocytoma 
and ependymoma, in which only a small percentage of the tumors harbors such 
mutations (Killela et al., 2013; Koelsche et al., 2013). The low frequency of TERT 
promoter mutations and telomerase activity in grades II and III astrocytomas can be 
explained by the high prevalence of ATRX mutations, one of the most frequent 
mutations in this type of gliomas (Jiao et al., 2012). It is known that ATRX mutations 
trigger ALT in astrocytoma cells and it has been shown that this alternative mechanism 
is frequently activated in astrocytomas, allowing telomere maintenance without the need 
for telomerase reactivation (Henson et al., 2005). In line with this, the frequency of 
TERT promoter mutations in secondary GBMs (that arise from the progression of lower 
grade astrocytomas) is considerably lower than in primary GBMs, that appear de novo 
(Nonoguchi et al., 2013).  
Furthermore, recent works about DNA methylation study at the TERT promoter 
identified a subset of five CpG sites (henceforth, upstream of the transcription start site 
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[UTSS]) that was hyper-methylated in all malignant paediatric brain tumours but not in 
normal tissues, increasing TERT expression and elongation of telomeres by reactivation 
of telomerase (Castelo-Branco et al., 2013). TERT promoter region UTSS was shown in 
Figure 3 (Fig. 3). In paediatric brain tumours, UTSS hyper-methylation is associated 
with tumour progression and poor prognosis. This region is easy to amplify, and the 
assay to establish hypermethylation can be done on most tissues in most clinical 
laboratories. Therefore, the UTSS region is a potentially accessible biomarker for 
pediatric brain tumors (Castelo-Branco et al., 2013). 
 
 
 
 
Fig. 3: The Illumina Infinium HumanMethylation450 array covers the area with the probes Cg17166338, 
Cg11625005 and Cg10896616. The amplified regions used for Sequenom and pyrosequencing (UTSS 
region) analyses are shown as open box and 36 bp sequence. Underlined are the 5 targeted CpG sites 
(from: Castelo-Branco et al., 2013).  
 
 
Tumors which do not activate telomerase utilize the less well-defined alternative 
lengthening of telomeres (ALT) phenotype which maintains telomeres in a telomerase-
independent manner, presumably by telomere-specific homologous recombination 
(Bechter et al., 2003; Mangerel et al., 2014; Nabetani et al., 2011). The molecular basis 
of activation of ALT are not yet fully known. It has been shown that during the 
replication-independent chromatin assembly, ATRX and DAXX proteins act together in 
the deposition and stabilization of histone H3.3 on DNA (Fig. 4).  
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Fig. 4: Mechanism of telomere length maintenance by ALT (a) or telomerase reactivation (c). The normal 
state was shown in figure b (from: Sturm et al., 2014). 
 
 
Next generation sequencing efforts have revealed a strong association of ATRX 
mutations in several adult tumors which exhibit ALT. ATRX is a protein involved in 
loading the histone 3 variant H3.3, the product of the H3f3a gene, at the telomeres, 
favouring formation of heterochromatin (Lovejoy et al., 2012; Schwartzentruber et al., 
2012). As ALT occurs by homologous recombination, loss of a heterochromatic state at 
the telomeres is permissive for this recombination to occur (Episkopou et al. 2014; 
Mangerel et al., 2014).  
Heaphy and colleagues observed the presence of ALT in brain tumors as 
medulloblastoma, schwannoma and glioblastoma, but its absence in all benign 
neoplasms and normal tissues (Ceccarelli et al., 2016; Heaphy, Subhawong et al., 2011; 
Mangerel et al., 2014). Later, they demonstrated that ATRX or DAXX mutations are 
16 
 
closely associated with the development of ALT in pancreatic endocrine tumors, 
whereas ATRX or H3.3 mutations lead to ALT phenotype in cancers of the central 
nervous system (Ceccarelli et al., 2016; Dong et al., 2012; Heaphy, de Wilde et al., 
2011). Mutations in ATRX and H3.3 have been reported also in pediatric gliomas, 
correlated with ALT activation and increase of telomere length (Fig. 5) (Dong et al., 
2012; Heaphy, de Wilde et al., 2011; Schwartzentruber J et al., 2012); however, their 
association and possible implication on the ALT phenotype in medulloblastomas were 
not so far investigated. 
 
 
 
Fig. 5: ALT positive and negative cases in Telo-FISH. Red signals evidenced telomeric sequences (from: 
Mangerel et al., 2014). 
 
 
ATRX, H3.3, TERT promoter mutations and UTSS methylation status could provide an 
explanation for the elongation of telomeres in most pediatric high-grade gliomas and 
metastatic medulloblastomas. 
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AIM OF THE STUDY 
 
 
Medulloblastomas and high-grade gliomas are the most frequent brain tumors in 
children; nowadays, research in the field of pediatric neuro-oncology is focused on 
biomolecular characterization of pediatric tumors, in order to treat these cancers more 
adequately.  
Medulloblastoma cells can disseminate through the cerebrospinal fluid in the 
leptomeningeal space; at present is not known which specific genetic/molecular 
alterations drive neoplastic cells to metastasize. Furthermore, in contrast to standard-
risk non-metastatic medulloblastoma, no gold standard treatment has been defined for 
metastatic cases.  
Our aim was to study specific molecular alterations involved in the processes of 
invasion, metastasis and cell survival in a series of 39 pediatric MDB with 
leptomeningeal dissemination at the onset and homogenously treated in a single 
institution, in order to define whether metastatic medulloblastomas are molecularly 
similar to non-metastatic ones, and whether could be identified genetic/molecular 
alterations involved in migration, invasiveness and malignancy of metastatic 
medulloblastoma cells. 
We analyzed several subgroup biomarkers from FFPE samples and we correlated results 
to outcome of patients (OS and PFS), in order to evaluate the prognostic relevance of 
the molecular biomarkers and subgroups in our cohort of 39 metastatic MDB; in fact, 
previous studies in literature on molecular subgrouping analysis included only small 
amount of metastatic cases, not analyzed independently from the non-metastatic 
counterpart.  
We analyzed FSTL5 gene expression to evaluate its significance as a high-risk 
biomarker associated with group 3/4 and bad outcome within our homogeneous cohort 
of pediatric patients with metastatic disease, since FSTL5 expression level was found to 
be closely correlated, in hepatocellular carcinoma as well as primary medulloblastoma, 
with tumor size, local infiltration and patient prognosis.  
Furthermore, in the light of the knowledge on the cell survival and senescence escape, 
we evaluated the possible activation of a pathway controlling elongation of telomeres in 
metastatic medulloblastoma cells. We compared our cohort of 39 metastatic MDB with 
56 pHGG, having different cellular origin but both with characteristics of high 
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malignancy, studying telomere length maintenance with telomerase reactivation or 
Alternative Lengthening of Telomeres (ALT); we analyzed H3.3, ATRX and DAXX, 
involved in ALT activation, along with the mutation and methylation status of TERT 
promoter. 
Telomeres elongation has been reported in pediatric gliomas, correlated with ALT 
activation, however it was not previously investigated in medulloblastomas with 
leptomeningeal dissemination at diagnosis.  For this reason, our goal was to analyze the 
activation of mechanisms involved in control of telomeres lengthening in metastatic 
cases, in order to figure out whether telomeres elongation could have a role in 
metastatic medulloblastoma cells. 
Ongoing comprehensive genome analysis will undoubtedly identify more genes 
involved in the pathogenesis of medulloblastomas and gliomas. Among those 
genetic/epigenetic changes, we aim to identify novel molecular markers or therapeutic 
targets that could be used for clinical decision making or development of more effective 
treatment. 
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MATERIALS AND METHODS 
 
 
Patients and tissue samples 
 
Formalin-fixed paraffin embedded (FFPE) tissue specimens from 55 pediatric high-
grade gliomas and 39 pediatric medulloblastomas with metastases at the onset were 
analyzed. All tumors were classified by four independent neuropathologists, according 
to the World Health Organization (WHO) classification of tumors of the central nervous 
system (Louis et al., 2007) using standard histological and immunohistochemical 
methods. 
Fifty-five pediatric high-grade gliomas included 28 glioblastomas (GBM; WHO grade 
IV), 11 anaplastic astrocytomas (AA; WHO grade III), 6 pilocytic astrocytomas (AP; 
WHO grade III), 5 high grade ganglioneuronal and 4 primitive neuroectodermic tumors 
(PNET), retrieved from 36 Italian surgery Departments; also 1 oligoastrocytoma (OA; 
WHO grade II) was analyzed.  
Medulloblastomas with metastasis at the onset were included in this study, were treated 
on the PNET4 /IT and were recruited from 1998 to 2014; age range was 3 to 21 years 
with median age of 12,5 years and an average follow-up of 155 months. The 
female/male ratio was 4/35. After complete surgical resection, patients received 
intensive sequential chemotherapy with high-dose methotrexate plus vincristine, high-
dose etoposide, high-dose cyclophosphamide and high-dose carboplatin, followed by 
craniospinal hyperfractionated accelerated radiotherapy (HART) with posterior fossa 
boost and a post-radiant phase consisting of lomustine and vincristine for a total 
duration of one year or two myeloablative courses with high-dose thiotepa, chosen 
according to the entity of the pre-radiant chemotherapy response (Gandola et al., 2009).  
Classical medulloblastomas were 30/39 (77%) cases of all tumors, followed by 
large/anaplastic (LC/A) histology with 7/39 (18%) and desmoplastic-nodular (D/N) 
with 2/39 (5%).  
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Immunohistochemistry (IHC)  
 
Evaluation of protein expression was performed via immunohistochemistry. IHC was 
carried out by streptavidin–biotin–immunoperoxidase technique on 3-μm sections of 
FFPE samples. Slides were deparaffinized in xylene, and rehydrated through a graded 
series of ethanol dilutions, then incubated for 15 mins in 3% H2O2 in methanol to 
inhibit endogenous peroxidases. Tissue sections were then incubated in 10% normal 
rabbit serum to block nonspecific antibody binding. Antigen retrieval was performed in 
a microwave for 3×5 min at full power in sodium citrate buffer for all antibodies. Tissue 
sections were then incubated overnight (16-18 hrs) with the primary antibody. Sections 
were washed and incubated with biotinylated anti-polyvalent secondary antibody 
(Ultratek, Sciteck) for 20 min at room temperature. This was followed by incubation for 
20 minutes with avidin–biotin peroxidase complex (Ultratek, Sciteck). Peroxidase 
activity was visualized by immersing sections in 0.03% 3.3′-diaminobenzidine–4HCl 
(UltraTek Kit, ScyTek) in 0.05 mol/l Tris–HCl buffer at pH 7.6 containing 0.005% H2O2 
for 10 min. The tissue sections were rinsed in distilled water, counterstained with 
hematoxylin, dehydrated with graded ethanol and xylene, and coverslipped. Different 
conditions were used for each primary antibody incubation. Primary antibody 
incubation was performed overnight with the following antibodies, shown in table 2 
(Tab. 1): GAB1 (1:300 dilution, ab27439, Abcam), YAP 1 (1:200, sc101199, Santa Cruz 
Biotechnology), Filamin A (1:500 dilution, PM6/317, Fitzgerald Industries 
International), β-catenin (1:600 dilution, ab15180, Abcam BD Transduction 
Laboratories n° 610154), NPR3 (1:300 dilution, ab37617, Abcam), KCNA1 (1:1000, 
ab32433, Abcam), OTX2 (1:100, 1H12C4B5, Thermo Fisher), ATRX (1:1000 dilution, 
NBP1-83077 Novus Biologicals, rabbit polyclonal) and DAXX (1:150 dilution, 
HPA008736 Sigma rabbit polyclonal). Protein expression was quantified by counting 
stained tumor cells and/or nuclei over 1,000 cells in tumor regions considered as the 
most immunoreactive to determine the labeling index (LI). Cases with ≤15% of stained 
tumor cell nuclei were considered suggestive to harbour an ATRX mutation. 
Cytoplasmic-only reactivity and granular nuclear reactivity were considered as negative. 
β-catenin was scored as positive when ≥15% of neoplastic nuclei where stained, with 
either negative or positive cytoplasm (Fattet et al., 2009). GAB1, YAP1 and Filamin A 
were scored as positive when ≥20% of neoplastic cells showed staining intensity >1, 
while OTX2 and KCNA1 was scored as positive when ≥30% of cells showed staining 
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intensity ≥1,5; NPR3 when ≥40% of cells showed staining intensity ≥2.  
 
ANTIGEN ANTIBODY DILUTION POSITIVITY 
GAB 1 ab27439, Abcam 1:200 
≥20% cells with staining 
intensity >1+ 
YAP 1 
sc101199, Santa Cruz 
Biotechnology 
1:300 
≥20% cells with staining 
intensity >1+ 
Filamin A 
PM6/317, Fitzgerald Industries 
International 
1:500 
≥20% cells with staining 
intensity >1+ 
β-catenin 
ab15180, Abcam BD Transduction 
Laboratories n° 610154 
1:600 
≥15% neoplastic nuclei with 
staining intensity ≥1+ 
NPR3 ab37617, Abcam 1:300 
≥40% cells with staining 
intensity ≥2+ 
KCNA1 ab32433, Abcam 1:1000 
≥30% cells with staining 
intensity ≥1,5+ 
OTX2 1H12C4B5, Thermo Fisher 1:100 
≥30% nuclei with staining 
intensity ≥1,5+ 
ATRX 
NBP1-83077 Novus Biologicals, 
rabbit polyclonal 
1:1000 
≤15% stained neoplastic nuclei 
were considered to harbour 
mutations 
DAXX 
HPA008736 Sigma rabbit 
polyclonal 
1:150 Uncertain IHC results 
 
Tab. 1: Antibodies used for IHC Analysis. 
 
DNA extraction, PCR and sequencing analysis for hot spot mutations of H3.3, 
TERT promoter and CTNNB1 
 
DNA from FFPE tumors was purified using the QIAamp DNA Mini Tissue Kit (Qiagen 
GmbH, Dusseldorf, Germany) according to the manufacturer's instructions after 
proteinase K digestion. Hematoxylin-Eosin (H&E) stained sections of each case were 
reviewed carefully by two independent neuropathologists before they were selected for 
DNA extraction. All samples selected contained at least 70% of vital tumor. Primers 
were designed to amplify the region containing TERT C228T and C250T hotspots, 
corresponding to the positions 124 and 146 Bp, respectively, upstream of the TERT 
ATG site. For H3.3 mutational analysis, primers contain the two mutations 
corresponding to LYS27 and GLY34. PCR conditions were for all the following: 
95°Cx15 min, 94°Cx30 sec, 60°Cx30 sec (40 cycles), 72°CX30 sec, 72°CX10 min and 
4°C. 5ul PCR fragments were then loaded on a 2% agarose gel and analyzed by 
Pyrosequencing. For Pyrosequencing analysis, single-stranded DNA templates were 
immobilized on streptavidin-coated Sepharose high-performance beads (GE Health 
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care, Uppsala, Sweden) using the PSQ Vacuum Prep Tool and Vacuum Prep Worktable 
(Biotage, Uppsala, Sweden), according to manufacturer’s instructions, then incubated at 
80°C for 2 minutes and allowed to anneal to 0.4 mmol/L sequencing primer at room 
temperature. Pyrosequencing was performed using PyroGold Reagents (Biotage) on the 
Pyromark Q24 instrument (Biotage), according to manufacturer’s instructions. Controls 
in which the sequencing primer or template were omitted were used to detect 
background signal. Pyrograms were analyzed by using the Pyromark Q24 software 
(Biotage) using the allele quantification (AQ) software to determine the percentage of 
mutant versus wild-type alleles according to percentage relative peak height. A 
mutational screening of H3F3A (hotspot codons 27 and 34) and TERT promoter 
(hotspots C228 and C250) were carried out as previously reported (Gessi et al., 2014; 
Gielen et al., 2013). Furthermore, Sanger direct sequencing method was performed for 
metastatic MDB cases on purified PCR-products, spanning the mutation cluster region 
in exon 3 of CTNNB1, encompassing sequences encoding amino acids 30 to 45. Primer 
sequences to specifically amplify β-catenin gene were designed to lead to amplimers 
that cover nucleotides 791-1070 in exon 3 of Genbank reference sequence X89579, 
giving a product of 288 bp (Legoix et al., 1999). Sequencing was performed using an 
automated sequencer ABI 3730 equipped with 48 capillaries (Applied Biosystems) on 
template with 10 pmol of each oligo-primers. All the primers were described in table 3 
(Tab. 2). 
 
H3.3-Pyro PCR 
 Primer forw: 5’ tgtttggtagttgcatatgg 3’ Primer rev: 5’Biotin- tacaagagagactttgtcc 3’ 
Primer pyro: 5’ caaaagccgctcgca 3’ 
 
  TERT mut -Pyro PCR 
 Primer forw: 5’ cctgccccttcaccttccag 3’ Primer rev: 5’ Biotin-aggacgcagcgctgcctgaa 3’ 
Primer pyro: 5’ accccgccccgtcccgacccc 3’ 
 
  CTNNB1 mut-PCR 
 Primer-forw: 5′ tggaaccagacagaaaagcg 3′ Primer rev: 5′ ggacagtatgcaatgactcga 3′ 
   
Tab. 2: Sequence of primers used for Pyrosequencing Analysis and PCR analysis for Sanger sequencing. 
 
 
23 
 
DNA extraction, bisulfite modification and methylation-specific PCR (MS-PCR) 
for analysis of TERT promoter methylation status 
 
The cohort analysed for UTSS methylation status consisted of 37 metastatic MDB and 
25 pHGG. A quasi-quantitative methylation specific polymerase chain reaction was 
used to determine methylation status relative at the five CpG island-rich regions. DNA 
samples were prepared using the QIAamp DNA Mini Tissue Kit (Qiagen GmbH, 
Dusseldorf, Germany) according to the manufacturer's instructions. DNA was 
quantitated by Nanodrop 2000 Spectrophotometer (Thermo Electron North America 
LLC, West Palm Beach, FL). Bisulfite-modification of DNA samples for methylation 
analysis was conducted using the EZ DNA Methylation Kit from ZYMO Research 
(Irvine, CA). The five CpG island-rich promoter regions, –600 bp upstream of the 
transcription start site (UTSS region), were targeted using specific primers to amplify 
bisulfite modified DNA. A total of 2 pairs of primers were used, each pair comprised of 
a forward and a reverse primer specific for un-methylated and methylated alleles (Tab. 
3). The primers targeting the un-methylated and methylated alleles yield 95 bp and 
90 bp PCR products, respectively. Please also refer to human genome Refseq 
NC_000005.10 for detailed sequence information. 
 
UTSS MS-PCR for methylated DNA 
 Primer-forw: 5′ cgtgcggcgattttttggtcgt 3′ Primer-rev: 5′ cgtaatacccgaaacccgacgc 3′ 
  
UTSS MS-PCR for un-methylated DNA 
 
Primer-forw: 5’ aggtgtgtgtggtgattttttggttgt 3’ Primer-rev: 5’ cataatacccaaaacccaacaccccac 3’ 
 
  
Tab. 3: Sequence of primers used for Methylation-specific PCR (MS-PCR) analysis, specific for un-
methylated and methylated alleles. 
 
 
To determine linearity of amplification to make the MS-PCR quasi-quantitative, we first 
serially diluted tumor DNA samples (100 ng, 50 ng, 25 ng, 10 ng, 5 ng, 2 ng). Each 
diluted DNA sample was PCR amplified using primers targeting the un-methylated and 
methylated alleles at CpG island-rich region. The DNA concentration that falls within 
the linear phase of PCR amplification as visualized on the agarose gel was determined 
and used for subsequent PCR amplifications and quantitation of the samples.  
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In each reaction, we used also normal brain tissue as negative control and 2 positive 
controls: one DNA fully methylated and one DNA completely un-methylated, supplied 
by Chemicon. PCR reagents including Hot Start Platinum Taq DNA Polymerase 
(Invitrogen) and PCRs were performed on an ABI GeneAmp 9700 thermocycler. PCR 
conditions consisted of initial denaturing at 95 °C for 3 minutes; 38 cycles of 94 °C for 
30 seconds, 58 °C for 30 seconds, 72 °C for 45 seconds, and final extension at 72 °C for 
7 minutes. The PCR products were run in 2% agarose gels and visualized under 
ultraviolet lights with appropriate intensities to avoid saturation. The gel images were 
photographed using transilluminator and imaging system (Hartland, WI) and the 
acquired gel images were analyzed and digitalized using ImageJ Software. We used the 
primarily generated digitalized data for the comparative analysis between methylated 
alleles and un-methylated alleles. The Mean Intensity of the bands was measured using 
ImageJ Software and the intensity of the bands for methylated DNA were compared to 
intensity for un-methylated DNA for each sample to assign a specific Methylation Value 
(MV). UTSS region was considered hyper-methylated when the MV was ≥30% of the 
un-methylated DNA.  
 
 
FSTL5 and ATRX gene expression analysis via RT-PCR 
 
Formalin-fixed paraffin embedded tissue samples from 33 MDB and 27 pHGG patients 
containing more than 70% tumor cells, as evaluated by a pathologist from hematoxylin-
eosin staining of sections, were included for gene expression analysis. Total RNA was 
extracted from tumor tissue sections using RNeasy FFPE Kit (Qiagen). For each 
sample, 0,25 μg of total RNA were reverse-transcribed using Superscript III 
(Invitrogen) with oligo(dT) priming according to the manufacturer's protocols. cDNA 
was then used as template in a 25 μl PCR reaction. Forward and reverse primers, shown 
in table 5 (Tab. 4), were designed on the bases of sequences deposited on NCBI for 
FSTL5 (Reference Sequence: NM_020116.4) and ATRX (Reference Sequence: 
NG_008838.1). To amplify the housekeeping gene HPRT1, used as internal reference 
control, was used the QuantiTect Primer Assay HPRT1 (Qiagen QT0059066), giving a 
product of 130 Bp. Each biomarker was amplified in parallel and simultaneously to the 
housekeeping gene for each patient sample analyzed. PCR cycling conditions were 
95°C for 5’, 35 cycles: 30” at 95°C, 30’’ at 56-58°C, and 45” at 72°C; final extension 7’ 
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at 72°C; finally, PCR products were visualized on a 2,5% agarose gel. The Mean 
Intensity of the bands for FSTL5 (133 bp) and ATRX (171 bp) was measured using 
ImageJ Software and compared with the intensity of the housekeeping band (HPRT1) 
for each sample to assign a specific Expression Value (EV). FSTL5, expressed at 
moderate levels in healthy brain tissue, was considered over-expressed when the EV 
was more than 110% of the EV housekeeping gene, down-expressed when the score 
was less than 90% of the EV housekeeping gene and normo-expressed when the score 
was between 110% - 90%. ATRX gene expression analysis was conducted in some 
cases to confirm results obtained via IHC.  
 
ATRX RT-PCR 
 Primer-forw: 5′ ccttgcacactcatcagaagaatc 3′ Primer-rev: 5′ cgtgacgatcctgaagacttgg 3′ 
  
FSTL5 RT-PCR 
 
Primer-forw: 5’ atgcagacggcataccaaag 3’ Primer-rev: 5’ tcttcatagcgcacatagct 3’ 
  
 
Tab. 4: Sequence of primers used for cDNA Semi-Quantitative Reverse Transcriptase-PCR analysis. 
 
 
Fluorescence in situ Hybridization (FISH) for MYC and MYCN 
 
Five-micron sections were cut from FFPE samples for FISH analysis of metastatic 
MDB. Slides were de-paraffinized in oven at 60°C for 60 min and incubated in xylene 
for 10 min. Slides were then dehydrated in ethanol and treated with pretreatment 
solution (1 mol/L sodium thiocyanate) for 30 min at 80°C; samples were immersed in 
pepsin solution (0,65% in protease buffer) for 20-30 min at 37°C, washed twice in 
buffer, and air-dried. The MYC or MYCN amplification was detected using LSI 
CMYC/CEP8 probe and LSI MYCN/CEP2 probe Vysis, in accordance with the 
manufacturer instructions (Abbott Laboratories). Sections were finally counterstained 
with DAPI, coverslipped, and stored in the dark at -20°C prior to analysis. FISH 
sections were examined with an Axio Imager M1 microscope (Carl Zeiss) equipped 
with Z-stack, using a 100x oil immersion objective, and analyzed by two investigators. 
Signals were counted in 100 tumor nuclei for each sample; an LSI/CEP signal ratio 
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between 1 and 2 was considered as gain. A signal ratio > 2 was considered as 
amplification. 
 
 
Telomere-specific fluorescence in situ hybridization (Telo-FISH) and analysis using 
TeloView System 
 
The presence of a canonical mechanism or alternative mechanism of telomere 
elongation has been investigated on consecutive sections, analyzing telomere length via 
FISH with FITC-PNA (Peptide Nucleic Acid) probes (Dako, K532511) complementary 
to the telomeric repeated sequences. The PNA probe does not recognize sub-telomeric 
sequences, allowing an exact measurement of the telomere length. Staining has been 
compared with endothelial cell nuclei as normal internal control.  
Five μm sections were cut from FFPE tissues for FISH analysis. Slides were 
deparaffinized in an oven at 60°C for 60 min and incubated in xylene. Slides were then 
dehydrated in 100% ethanol for 5 min at room temperature (RT) and treated for 20 min 
at RT in 0.2 mol/L HCl, then with pre-treatment solution (1 mol/L sodium thiocyanate) 
for 30 min at 80°C. Slides were then incubated with 1 mg/mL pepsin in 0.01 mol/L HCl 
for 20 min at 37°C. The sample DNA was denatured at 80°C for 5 minutes together with 
fluorescein conjugated PNA probe. The hybridization was at 37°C for 2 hours, followed 
by a brief wash with a stringent solution at 65°C for 5 minutes. Cover slips were 
mounted with 2 x 10 μL antifade reagent containing DAPI as counterstain. FISH 
sections were examined with an AxioImager M1 microscope (Carl Zeiss Jena, 
Germany), using a 100x oil immersion objective and analyzed by two investigators. 
Signals were counted for at least 100 tumor cells; deconvolved images were converted 
into TIFF files and exported for telomere specific image analysis using the TeloView 
software program. 
TeloView was a quantitative program that measures telomeres intensity within the 
nuclear space. Nuclear telomere analysis using TeloView determined the telomere 
numbers, telomere signal intensities and nuclear telomere distribution for each case. 
Quantitative telomere analysis was performed on ≥100 nuclei for patient. The integrated 
intensity of each telomere is calculated because it is proportional to the telomere length. 
A mean intensity of telomeres was measured for each case by TeloView, comparing 
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each telomere signal intensity with numbers of telomeres. We used positive and 
negative control cases for lengthening of telomeres to establish a threshold.  
TeloView indicated the presence of two different telomeric profiles that are shown in 
figure 4 (Fig. 6), displaying significant differences in telomere length (p value<0,001) 
and number of telomeric aggregates for positive controls (brain tumors previously 
analysed with canonical or ALT activation) and negative controls (non-neoplastic brain 
tissues). 
 
 
 
 
Fig. 6: Quantitative telomere analysis of positive and negative control cases using software TeloView. 
Spots evidenced the mean fluorescent intensity of each case. 
 
 
Statistical analysis for overall survival and progression free survival 
 
The association between categorical variables was tested using the Chi-square test. 
Overall survival (OS) and progression-free survival (PFS) were estimated using 
Kaplan–Meier method calculated from time of surgery. Overall survival was determined 
from the date of diagnosis to the date of death or last follow-up visit before death. PFS 
time was the interval from the date of starting chemotherapy to the date of progression 
or death, whichever occurred first, with censoring at the latest follow-up visit for alive 
and progression-free patients. The log-rank test was used to compare survival 
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information according to the prognostic factors. The multivariate Cox proportional 
hazards regression model was used to test the effect of prognostic factors on OS and 
PFS. 
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RESULTS 
 
 
Molecular classification of metastatic medulloblastomas 
 
Molecular subgrouping  
 
According to the consensus molecular classification and biomarkers reported for MDB, 
we enrolled our samples in one of the four molecular subgroups, except 3 cases for 
which it was not possible to perform the analysis. We identified 5 WNT (14%), 7 SHH 
(19%), 9 group 3 (25%) and 6 group 4 (17%) cases; 9 MDB (25%) analyzed were not 
classified (N.C.) because did not share a define molecular profile with any of the four 
molecular subgroups.  
Cases with triple immuno-positivity for GAB1, YAP1 and Filamin A were attributed to 
the SHH group; this molecular subgroup showed also 28% of cases with MYC 
amplification. Nuclear translocation of β-catenin identified WNT cases; OTX2 immuno-
positivity also characterized group WNT medulloblastomas. CTNNB1 Sanger 
Sequencing was performed to evaluate mutations on exon 3, to confirm the presence of 
specific mutations that are involved in nuclear translocation of β-catenin. Results 
showed that no case (0/5, 0%) with nuclear immuno-positivity for β-catenin harbored 
mutations on cluster region in exon 3 of CTNNB1 gene, indicating that other 
mechanisms could be involved in β-catenin nuclear translocation and activation of WNT 
pathway in pediatric metastatic MDB. Immuno-positivity for NPR3 and OTX2, 
immuno-negativity for YAP1 and Filamin A, and amplification of MYC gene identified 
group 3 cases; amplification of MYC characterized 75% of group 3 cases, a higher 
frequency compared to the other subgroups.  Group 4 cases were identified by immuno-
positivity for KCNA1 and OTX2, immuno-negativity for YAP1 and Filamin A, and low 
expression of NPR3, which discriminate group 4 cases from group 3. Amplification of 
MYCN gene characterized only one case in our series of metastatic MDB, classified in 
group 4; no case of group 4 showed MYC amplification. MYC amplification was 
detected in 32.5% of our cases, a higher frequency compared to MYCN amplification 
(3%), while simultaneous amplification of both MYC and MYCN was not shown in any 
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case of our cohort (Fig. 8). Summary of IHC results and distribution within molecular 
subgroups was shown in figure 7 (Fig. 7).  
 
 
 
Fig. 7: Summary table of IHC presence/absence of proteins and distribution in molecular subgroups. 
 
 
 
Fig. 8: Metastatic MDB selected cases with MYC not amplified (A), MYC amplification (B), MYCN not 
amplified (C) and MYCN amplification (D). MYC and MYCN probes were labelled with red fluorescent, 
CEP8 and CEP2 probes, using as internal references, were labelled in green.  
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Survival analysis of molecular subgroups 
      
Kaplan–Meier curves of MDB subgroups obtained by molecular analysis were shown in 
figure 9 (Fig. 9). WNT and NC patients showed longer OS and PFS compared to the 
other molecular subgroups. The overall survival of group WNT and NC MDB was 
100% in the first 70 months of treatment, furthermore no WNT or NC case relapsed in 
the first 40 months. The outcome of WNT and NC molecular subgroups of metastatic 
MDB was favorable, with a survival rate over 80% after a follow-up of 160 months. 
Conversely, SHH, group 3 and 4 medulloblastomas showed a similar trend in term of 
survival and were related to a worse outcome compared to WNT and NC, with a 
survival rate less than 60% after a follow-up of 160 months. The differences in terms of 
OS and PFS between WNT and NC MDB with group SHH, 3 and 4 cases were 
statistically significant (p value<0,05). 
Finally, we also correlated the expression of each biomarkers with OS and PFS of 
patients (data not shown); none of the biomarkers analyzed showed significant 
association with outcome of metastatic cases. 
 
 
 
 
Fig. 9: Kaplan–Meier OS and PFS curves according to molecular subgroups: overall survival (solid line) 
and progression-free survival (dotted line). N.C. = not classified cases. 
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FSTL5  
 
With the aim to investigate some molecular aspects involved in aggressiveness and 
invasion pathway in pediatric brain tumors, we analyzed the gene expression of FSTL5, 
a high-risk biomarker in primary MDB. 
 
FSTL5 expression in metastatic MDB  
 
Previous study revealed that FSTL5 play a role in MDB and was over-expressed in 
group C and high-risk group D tumors. FSTL5 over-expression was also significantly 
associated with reduced progression-free and overall survival across all disease variants 
in medulloblastomas not exclusively metastatic (Gilbertson et al., 2011; Northcott et al., 
2011; Shih et al., 2014; Remke et al., 2011a). We evaluated FSTL5 expression levels 
and prognostic value in a series of MDB all with metastasis at the onset; FSTL5 
expression analysis in our cases showed 9/33 (27%) metastatic MDB with over-
expression, while 11/33 (34%) cases were characterized by down-expression; other 
cases showed FSTL5 normo-expression (13/33; 39%). Variation on FSLT5 expression 
levels among MDB cases was shown in figure 10 and 11 (Fig. 10 and Fig. 11). The 
difference between FSTL5 down-expression, normo-expression and over-expression 
cases was statistically significant (p value<0,001).  
 
 
 
Fig. 10: A: Metastatic MDB selected cases with FSTL5 over-expression, down-expression and normo-
expression compared to housekeeping gene HPRT1 in RT-PCR. 
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Fig. 11: Relative quantification of FSTL5 expression levels in metastatic MDB. 
 
 
 
Group 3 and 4 metastatic MDB were characterized by higher expression levels of 
FSTL5 compared to WNT, SHH and NC subgroups (Fig. 12). The differences in 
expression levels of group 3/4 cases compared to the other subgroups were statistically 
significant (p value=0,006). FSTL5 expression analysis was performed also in 12 
pediatric high-grade gliomas (pHHG), to compare results with those obtained for 
metastatic MDB. Medulloblastomas showed an over-expression in 27% of cases, while 
none of pHHG tested (0/12, 0%) for gene expression highlighted an over-expression, 
suggesting that FSTL5 is mostly expressed in brain tumors such medulloblastomas, and 
not in glia-derived tumor. 
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Fig. 12: Relative quantification of FSTL5 expression levels within different molecular subgroups. 
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Survival analysis and prognostic value of FSTL5 expression 
 
Kaplan-Meier test revealed that metastatic MDB with high expression levels of FSTL5 
correlated with worse prognosis compared to FSTL5 down-expression and normo-
expression cases. Medulloblastomas with FSTL5 low-expression showed a survival rate 
around 90%, while cases with over-expression were characterized by a survival rate less 
than 50% after a follow-up of 160 months (Fig. 13); the differences, in terms of OS and 
PFS, were statistically significant (p value<0,05).  
 
 
 
 
Fig. 13: Kaplan Meyer analysis of overall survival (a) and progression-free survival (b) according to 
FSTL5 expression levels in metastatic MDB. 
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FSTL5 molecular mechanism involved in tumor growth and cellular migration 
 
FSTL5 is a biomarker for MDB, however, its biological functions and molecular 
mechanisms in cancer development are poorly understood. FSTL5 is a secretory protein 
with sub-cellular localization. The molecular function of FSTL5 was not so clear, but 
this gene includes calcium ion binding domain. Calcium-binding proteins participate 
in calcium cell signalling pathways by binding to Ca2+, the calcium ion that plays an 
important role in many cellular processes. FSTL5 has calcium-ion-storage activity, 
interacting selectively with Ca2+ and might be involved in regulating tumor 
microenvironment; in fact, calcium signalling can be activated in cells with pathological 
conditions, leading to environment changing (Yang et al., 2010). Remodel of Ca2+ 
homeostasis affects cell cycle regulators, such p21 and Cdc25C, leading to tumor 
growth and angiogenesis; furthermore, high extracellular levels of Ca2+ promote Ras 
and Rac1 activity, Pyk2 phosphorylation and activation of others calcium ions 
dependent effectors involved in cell migration and invasion. Elevated extracellular Ca2+ 
can also activate calcium-sensing receptors (CaSR), that increase phosphorylation of 
ERK2 and Akt promoting b1-integrin cell surface expression and cellular migration 
(Tharmalingam et al., 2016).  
We hypothesize a molecular mechanism, shown in figure 14 (Fig. 14), in which FSLT5 
over-expression leads to increase secretion of this protein binding Ca2+, that affects 
tumor microenvironment and sustains the most aggressive MDB cells associated with 
high risk subgroups.  
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Fig. 14: Our hypothesis of FSTL5 molecular mechanism by binding Ca2+, triggering the activation of 
several pathways involved in cellular migration, angiogenesis and proliferation. 
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Control of telomeres elongation in metastatic MDB and pHGG 
 
Study of telomere lengthening control and pathways involved in senescence escape was 
conducted to evaluate molecular and genetic bases of these mechanisms in aggressive 
form of pediatric brain tumors. We screened a cohort of 39 pediatric metastatic MDB 
and a series of 55 pHGG for evidence of telomere length elongation, using telomere-
specific FISH (Telo-FISH). Since the presence of mutations in ATRX results in loss of 
nuclear expression, we assessed the nuclear staining via IHC (Fig. 15). H3.3 and TERT 
promoter hot spot mutations were analyzed by pyrosequencing (Fig. 16 and Fig. 17, 
respectively), while epigenetic status of UTSS region was analyzed by methylation-
specific-PCR (Fig. 18). Regarding DAXX protein expression analysis, the lack of 
reproducibility of the IHC technique for DAXX immunostaining made dubious and 
uncertain our results, both for metastatic MDB and pHGG. Results obtained for DAXX 
were not considered for telomere lengthening activation (data not shown).  
 
 
 
Fig. 15: A) 100% nuclear immunopositivity for ATRX in a selected case on TMA. B) Selected case with 
nuclear immunonegativity for ATRX (arrows indicate endothelial cells as internal positive control). C) 
Selected case with ATRX down-expressed in RT-PCR. D) Selected case with ATRX over-expression in 
RT-PCR. (HkG: HPRT1 housekeeping gene). 
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Fig. 16: From the top: Selected WT case, Selected case with H3.3 K27M mutation and selected case with 
H3.3 G34R mutation. 
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Fig. 17: From the top: Selected WT case, Selected case with TERT C228T mutation and selected case 
with TERT C250T mutation. 
 
 
 
 
 
 
Fig. 18: Selected cases with UTSS hyper-methylated (Case 1 and 2) and not methylated (Case 3) in MS-
PCR; positive and negative controls were included in each experiment. 
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Genetic and molecular alterations of factors involved in pathways of telomere length 
control  
 
Among metastatic MDB, none of these cases showed H3.3 mutations (0/20, 0%), while 
6 cases (6/29; 20,6%) showed TERT mutations: 5 cases with TERT C250T mutation and 
1 with TERT C228T mutation. ATRX nuclear loss characterized 28% (7/25) metastatic 
medulloblastomas. Study of TERT promoter methylation status in UTSS region showed 
that 22 metastatic MDB (22/37, 59,5%) were characterized by hyper-methylation, with 
a methylation value ≥30%. Pediatric high-grade gliomas showed the presence of H3.3 
mutations in 9 cases (9/42, 21,4%): 6 cases with LYS27 mutation and 3 with GLY34 
mutation. TERT mutations characterized only 2 cases (2/26, 7,6%) of pHGG analyzed, 
all with C250T mutation; loss of ATRX nuclear expression was evidenced in 11 pHGG 
(11/52, 21%), that did not show nuclear staining. We used a RT-PCR analysis approach 
for confirming some samples (n=7) in which the IHC staining for ATRX was unclear; 
gene expression confirmed IHC results in analyzed cases. Furthermore, 7 pHGG (7/25, 
28%) were hyper-methylated in UTSS region of TERT.  
These findings underlined that hyper-methylation in UTSS region was more frequent in 
metastatic MDB, as well as TERT promoter mutation, compared to pHGG. Conversely, 
H3.3 mutations did not characterize metastatic medulloblastomas but only pHGG; 
ATRX nuclear loss was shown both in metastatic MDB and pHGG, with similar 
incidence. Notably, ATRX loss and TERT mutations were mutually exclusive, except 
for one medulloblastoma case. Within molecular subgroups of metastatic 
medulloblastomas, alterations in different factors involved in control of telomere 
elongation were found in all molecular subgroups, with less frequencies in subgroup 
four, regarding TERT promoter mutations and UTSS hyper-methylation. Within pHGG, 
the percentage of cases with ATRX, H3.3, TERT and UTSS alterations differed 
according to the histopathological type of tumors. H3.3 mutations, TERT promoter 
mutations and ATRX nuclear loss were detected in most cases of GBM and AA, in 
contrast to other histologies which include 6 pilocytic astrocytomas, 5 ganglioneuronal 
and 4 primitive neuroectodermic tumors, and 1 oligoastrocytoma. Furthermore, UTSS 
hyper-methylation characterized GBM with high incidence, in contrast to anaplastic 
astrocytomas and other histologies, in which only a small percentage of the tumors 
harbored this alteration.  
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Elongation of telomeres  
 
Metastatic MDB and pHGG cases with alterations in telomeres lengthening control 
pathways were tested via Telo-FISH to evaluate the elongation of telomeres (Fig. 19); 
cases with no alterations in ATRX, H3.3 or TERT were also analyzed.  
 
 
 
Fig. 19: Telo-FISH analysis of telomere length in metastatic MDB (A, C) and pHGG (B, D). Green 
signals evidenced telomeric sequences. Representative images of telomere-specific fluorescence in situ 
hybridization show elongation of telomere length in metastatic MDB (C) and pHGG (D) versus tumor 
cells with basal levels of telomere length in medulloblastomas (A) and high-grade gliomas (B). 
 
 
Metastatic MDB showed 9 cases (9/22, 41%) with elongation of telomeres; pHGG were 
characterized by 40% of cases (12/30) with increase of telomere length. All other cases 
showed basal levels of telomere length, with significantly reduced intensity of 
fluorescence signals. These findings underlined that elongation of telomeres 
characterize both metastatic medulloblastomas and pediatric high grade gliomas with 
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similar incidence. Within molecular subgroups of MDB, cases with telomere length 
increasing were found in all molecular subgroups, with less frequency in subgroup 4; 
while, among pHGG, telomere elongation was detected with high incidence in GBM 
and AA, in contrast to other histologies in which no case (0%) showed increase of 
telomere length. 
Results of ATRX nuclear loss, H3.3 and TERT promoter mutations, UTSS hyper-
methylation and elongation of telomeres in metastatic MDB and pHGG, stratified by 
molecular subgroups and histological diagnosis, were shown in table 5 (Tab. 5). 
 
 
 
 
Tab. 5: Summary of results for ATRX, H3.3, TERT, UTSS and telomere elongation, with frequency of 
alterations within metastatic MDB and pHGG. 
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Canonical elongation of telomeres, ALT detection and association with ATRX, H3.3, 
TERT and UTSS alterations 
 
We used a software program (TeloView) that measures telomere intensity signals within 
the nuclear space to determine telomeres elongation in our cases. Positive and negative 
control cases were used to establish a threshold and to identify different telomeric 
profiles, indicative of cases with increase of telomere length or not. 
Twenty-two metastatic medulloblastomas were analysed and the mean intensity of 
telomeres for each case was measured. Results (Fig. 20) showed that cases with ATRX 
nuclear loss were always associated with telomere elongation (6/6, 100%), with a 
significantly increased fluorescence signals, comparable to intensities of the positive 
controls and indicative of ALT activation.  
Medulloblastomas with TERT promoter mutations were correlated with increase 
telomere length (4/5, 80%), but only in cases with UTSS hyper-methylated. Canonical 
pathway of telomere elongation via telomerase reactivation was shown in metastatic 
MDB with TERT promoter mutations in combination with hyper-methylation of UTSS; 
telomere elongation was not present when TERT promoter was mutated but UTSS 
region was un-methylated. Telomere elongation was not found in cases without 
alterations of TERT or ATRX (0/12, 0%); all these wild type cases showed a 
significantly reduced fluorescence signals and the mean intensities of telomeres were 
comparable to those of the negative controls. Furthermore, UTSS hyper-methylation in 
metastatic MDB was not sufficient alone to activate elongation of telomeres.  
The differences in telomere length of cases with ATRX alterations compared to wild 
type medulloblastomas were statistically significant (p value=0,0019). 
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Fig. 20: Quantification of fluorescence intensity of telomeres for metastatic medulloblastomas within 
different groups characterized by ATRX nuclear loss, TERT promoter mutations or no alterations. 
Analysis of telomere length for positive and negative control cases were included. 
 
 
Thirty pediatric high-grade gliomas were also analysed to measure the mean intensity of 
telomeres for each case. Results (Fig. 21) showed that telomere elongation was present 
in all cases with ATRX nuclear loss (9/9, 100%). Elongation was found also in cases 
with positive nuclear staining for ATRX, in presence of H3.3 GLY34 or H3.3 LYS27 
mutations. All cases with mutated H3.3 GLY34 were correlated with increase telomere 
length (3/3, 100%), while only 2 patients with H3.3 LYS27 mutation were associated 
with elongation of telomeres (2/6, 33,3%). These findings highlighted that mutations in 
GLY34 of histone H3.3 and/or ATRX nuclear loss always activated ALT and increased 
telomere length of pHGG. Telomere elongation was not present when TERT promoter 
was mutated (0/2, 0%); furthermore, telomere length increase was not shown in cases 
with no alterations of TERT, H3.3 or ATRX (0/12, 0%). Wild type and TERT mutated 
cases showed a significantly reduced fluorescence signals, with the mean intensities of 
telomeres comparable to those of the negative controls. In pHGG, as well as in 
metastatic MDB, UTSS hyper-methylation alone did not activate elongation of 
telomeres.  
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The differences in telomere length of cases with ATRX and/or H3.3 alterations, 
compared to TERT mutated and wild type gliomas, were statistically significant (p 
value=0,0066). 
  
 
 
 
Fig. 21: Quantification of fluorescence intensity of telomeres for pediatric high-grade gliomas within 
different groups characterized by ATRX nuclear loss and/or H3.3 mutations, TERT promoter mutations or 
no alterations. Analysis of telomere length for positive and negative control cases were included. 
 
 
Our results highlighted that metastatic medulloblastomas could control elongation of 
telomeres via canonical pathway of telomerase reactivation (3/22, 13,6%), induced by 
TERT promoter mutations in combination with UTSS hyper-methylation, or ALT 
mechanism (6/22, 27,3%), induced by ATRX alteration; while, our pediatric high-grade 
gliomas increased telomere length only via the alternative pathway ALT (12/30, 40%), 
induced by ATRX or H3.3 alterations. 
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DISCUSSION  
 
 
This research was conducted to investigate a large cohort of medulloblastomas with 
leptomeningeal dissemination at the onset. Nowadays, research in the field of pediatric 
neuro-oncology is focused on biomolecular characterization of pediatric tumors to treat 
these cancers more adequately.  
Various studies indicated molecular subgrouping correlation with age distribution, 
biological behavior and prognostic stratification of MDB (Ellison et al., 2011a; Ellison 
et al., 2011b; Ellison et al., 2005; Kool et al., 2008; Korshunov et al., 2012; Northcott et 
al., 2011; Northcott at al., 2012a; Ramaswamy et al., 2016; Remke et al., 2011a and b; 
Robinson et al., 2012; Taylor et al., 2012). These studies included only a small 
percentage of metastatic cases at the onset; in fact, the percentage of metastatic cases 
did not exceed 30% and were not studied independently from the non-metastatic 
counterpart. 
In this work, we analyzed a series of 39 pediatric metastatic MDB according to the 
molecular classification consensus (Ellison et al., 2011a; Ellison et al., 2011b; Northcott 
at al., 2012b; Ramaswamy et al., 2016; Taylor et al., 2012). In order to classify our 
metastatic cases according to molecular subgroups, we evaluated protein expression of 
GAB1, YAP1, Filamin A, β-catenin, NPR3, OTX2 and KCNA1, gene expression levels 
of FSTL5 and amplification of MYC and MYCN gene, with a sub-classification system 
widely available.  
We identified 14% WNT, 19% SHH, 25% group 3 and 17% group 4 cases, while 25% 
of MDB analyzed were not classified (N.C.) on the basis of these biomarkers; molecular 
classification highlighted the presence of metastatic medulloblastomas in WNT 
subgroup, characterized by nuclear translocation of β-catenin (Fattet et al., 2009) and 
absence of FSTL5 over-expression. CTNNB1 Sanger Sequencing, performed to 
evaluate mutations on exon 3 in cases with nuclear translocation of β-catenin, showed 
that 0/5 (0%) cases with nuclear immuno-positivity for β-catenin harbored mutations on 
cluster region in exon 3 of the gene. Despite the absence of mutations, WNT cases 
highlighted a good prognosis, indicating that also other mechanisms could be involved 
in β-catenin nuclear translocation and could influenced outcome of patients.  
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Evaluation of nuclear translocation of β-catenin by IHC in metastatic MDB allowed a 
good sub-classification of patients and risk stratification of cases. 
Various studies showed molecular subgrouping correlation with outcome of pediatric 
patients, but some survival information remain unknown for metastatic MDB 
(Ramaswamy et al., 2016). Recently, the relevance of subgroup status and biologic 
parameters (WNT/MYCC/MYCN status) in a homogeneous prospective trial population 
of 121 metastatic MDB was confirmed (Van Bueren et al., 2016), showing the 
prognostic role of WNT activation in metastatic disease. Four patients with metastatic 
WNT-activated medulloblastoma survived without relapse, indicating that WNT-
metastatic MDB may be treated successfully by less intensive treatment regimens 
(standard risk protocol) (Van Bueren et al., 2016).  
Biomarkers analysis allowed us to identify five WNT metastatic cases in our cohort, 
associated with good outcome with a survival rate >80% after a follow-up of 160 
months. Molecular classification was useful to identify WNT metastatic 
medulloblastomas and define outcome of these cases, considered standard risk patients 
as recently proposed in literature (Van Bueren et al., 2016). Not classified 
medulloblastomas, a subgroup of metastatic MDB that did not share a define molecular 
profile with any of the four molecular subgroups, were related also to good prognosis, 
similar to WNT group.  
In literature, group 3 cases with metastasis at the onset have been identified as being 
very high risk, while metastatic cases of group SHH and group 4 were considered high 
risk patients (Ramaswamy et al., 2013; Ramaswamy et al., 2016; Shih et al., 2014; Van 
Bueren et al., 2016). Our results confirmed this risk stratification of patients with 
metastatic spread at diagnosis; in fact, our survival curves for SHH, group 3 and 4 
cases, obtained with molecular classification, showed all an association with bad 
outcome and survival rate <60% after a follow-up of 160 months.  
FSTL5 over-expression in MDB, with other factors of malignancy such MYC/MYCN 
amplification, was associated with high risk subgroups and correlated with poor 
prognosis (Gilbertson et al., 2011; Northcott et al., 2011; Remke et al., 2011a). This 
work confirmed that FSTL5 expression can be used as an excellent marker for 
discrimination of metastatic MDB in different molecular subgroups: group 3 and group 
4, characterized by FSTL5 high expression levels, and group SHH/WNT/NC, 
characterized by FSTL5 low expression levels. Furthermore, survival curves showed an 
association between over-expression of FSTL5 and bad outcome of patients, 
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characterized by a survival rate <50%, while medulloblastomas with FSTL5 down-
expression highlighted a survival rate of 90%.  
We showed that FSTL5 is an independent prognostic marker for metastatic MDB; 
furthermore, none of pHHG tested for FSTL5 gene expression highlighted an over-
expression, suggesting that FSTL5 is mostly over-expressed in medulloblastomas and 
not in glia-derived tumor. 
FSTL5 is a second effector of cell survival, proliferation and migration; it’s a secret 
glycoprotein which regulates activin and other TGFβ family members. We hypothesized 
that FSTL5 interacts with Ca2+ in extra-cellular space and regulates tumor 
microenvironment. Calcium, as extra-cellular messenger, is essential signal transduction 
element (Yang et al., 2010) and the dysregulation of Ca2+ homeostasis is an important 
event in driving the expression of the malignant phenotypes, such as proliferation, 
migration, invasion, and metastasis (Yih-Fung Chen et al., 2013; Tharmalingam et al., 
2016).  
In conclusion, calcium dysregulation induced by FSTL5 over-expression can trigger to 
migration, invasiveness and malignancy in high-risk subgroups of metastatic MDB. The 
addition of FSTL5 expression analysis to existing molecular stratification schemes can 
be considered a reliable tool for prognostic evaluation in clinical trials of 
medulloblastomas with metastatic spread at diagnosis. 
In the light of the knowledge on the cell survival and senescence escape, we also 
investigated molecular mechanisms to maintain telomere length in pediatric brain 
tumors, especially in medulloblastomas with leptomeningeal dissemination at the onset; 
in fact, our goal was to analyze the possible activation of mechanisms involved in 
control of telomere lengthening, via telomerase reactivation or ALT. 
Elongation of telomeres is necessary for tumor cell immortalization and senescence 
escape; this could be obtained by a reactivation of telomerase or by a telomerase-
independent pathway called ALT (Ceccarelli et al., 2016; Cesare et al., 2010; Koelsche 
et al., 2013; Mangerel et al., 2014; Remke, Ramaswamy et al., 2013). ALT mechanism 
is due to alterations in H3.3 or ATRX genes, reported in pediatric gliomas and 
correlated with increase of telomere length (Heapy, de Wilde et al., 2011; Heapy, 
Subhawong et al., 2011; Schwartzentruber J et al., 2012). 
We screened a cohort of 39 pediatric metastatic MDB and 56 pHGG to evaluate the 
length of telomeres, ATRX nuclear loss, H3.3 and TERT promoter mutations and UTSS 
methylation status. The understanding of molecular mechanisms to maintain telomere 
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length in PBT, especially in metastatic medulloblastomas, can improve knowledge 
about tumour cells escape from replicative senescence. 
Previous studied revealed that ALT was highly activated in high-grade gliomas, but 
rarely found in medulloblastomas (Dorris et al., 2014; Mangerel et al., 2014). We 
observed ALT in our cohort of pediatric high grade gliomas (40%), associated with 
H3.3 and ATRX alterations. ALT was not found only in pHGG, but it was a mechanism 
activated also in pediatric metastatic medulloblastomas with high incidence (27,3%). 
ALT pathway is activated with higher frequency in our metastatic cases compared to 
non-metastatic medulloblastomas analysed in literature (<5%) (Dorris et al., 2014; 
Mangerel et al., 2014). The observation that ALT is highly activated in MDB with 
metastasis highlights the biological differences between metastatic and non-metastatic 
medulloblastomas in control of telomere elongation, cells immortalization and 
senescence escape. 
As reported in literature (Ceccarelli et al., 2016; Ebrahimi et al., 2016; Gielen et al., 
2013; Heapy, de Wilde et al., 2011), telomeres length elongation was strongly 
correlated with ATRX nuclear loss in our work, showing a significantly increased 
intensity of fluorescence signals indicative of ALT. H3.3 mutations, considered a 
driving oncogenetic event in a significant subgroup of pHGG (Sturm et al., 2012), did 
not affect our medulloblastomas (0%), suggesting that telomere elongation by ALT is 
only activated via ATRX alterations in metastatic MDB. As previously analyzed in 
literature (Gielen et al., 2013; Heapy, de Wilde et al., 2011; Schwartzentruber J et al., 
2012), we observed H3.3 mutations in pHGG; however, these mutations were not 
always associated with elongation of telomeres. Results highlighted that mutations in 
GLY34 of histone H3.3 were always correlated with increase telomere length (100%), 
while H3.3 LYS37 mutations activated ALT with less incidence (33,3%).  
Most cancers maintain their telomere length through reactivation of telomerase and not 
ALT, triggered by specific mutations in the TERT promoter; however, this is 
uncommon in pediatric cancer (Killela et al., 2013; Koelsche et al., 2013). As reported 
in previous studies (Killela et al., 2013; Koelsche et al., 2013; Nonoguchi et al., 2013), 
TERT promoter mutations were rare in our cohort of pHGG (7,6%), while pediatric 
metastatic medulloblastomas harboured these alterations more frequently (20,6%). 
Previous work conducted on primary medulloblastomas reported a high frequency of 
TERT mutation in SHH subgroup (Remke, Ramaswamy et al., 2013). Conversely, we 
found that all molecular subgroups of metastatic medulloblastomas were characterized 
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by alterations in ALT-activating factors or telomerase, with less frequency for subgroup 
4.  
Furthermore, a specific region of TERT promoter called UTSS was found to be hyper-
methylated in high grade brain tumors and not hyper-methylated in normal tissues and 
low-grade tumours in literature (Castelo-Branco et al., 2013). Our results underlined 
that hyper-methylation in UTSS region was more frequent in metastatic MDB (59,5%) 
compared to pHGG (28%), as well as TERT promoter mutation. Within our gliomas 
cohort, UTSS hyper-methylation characterized GBM with high incidence (37,5%), in 
contrast to astrocytomas and other histologies, in which only a small percentage of 
tumors harbored this alteration. Our results support the finding that UTSS hyper-
methylation is associated with tumour progression and aggressive histological variants 
of pediatric brain tumors. 
Previous study suggested that hyper-methylation of UTSS cause also over-expression of 
TERT to maintain telomere length in PBT (Castelo-Branco et al., 2013). We showed 
that hyper-methylation in UTSS region was not sufficient alone to activate elongation of 
telomeres. We also evidenced that TERT promoter mutations were not always 
associated with elongation of telomeres; TERT promoter mutations correlated with 
increase of telomeres length only in association with UTSS hyper-methylation in our 
medulloblastomas. This observation suggested that TERT promoter mutations and 
UTSS hyper-methylation act together, increasing TERT expression and telomeres length 
via telomerase reactivation for metastatic MDB (13,6%).  
In conclusion, we found cases with elongation of telomeres in our cohorts of metastatic 
medulloblastomas (41%,) and pediatric high grade gliomas (40%). We highlighted that 
medulloblastomas with metastasis at the onset could control elongation of telomeres 
both via canonical pathway of telomerase reactivation, induced by TERT promoter 
mutations in combination with UTSS hyper-methylation, or ALT mechanism, induced 
only by ATRX alterations and not H3.3 mutations. There was almost mutual exclusivity 
between ALT and TERT promoter mutations for all analysed cases. Results for 
pediatric high grade gliomas suggested that pHGG did not elongate telomeres via 
telomerase reactivation (0%), but exclusively via the alternative pathway ALT, induced 
by ATRX and/or H3.3 alterations. Therefore, pediatric metastatic medulloblastomas 
seem to have a major activation of the canonical pathway and different involvement in 
molecular control of telomeres elongation compared to pediatric gliomas.  
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Recent data showed that ALT activation could attenuate the poor outcome in some 
pediatric brain tumors (Ceccarelli et al., 2016; Dorris et al., 2014); analysis of telomere 
length maintenance via telomerase or ALT may contribute to risk stratification of 
patients and targeted therapies to improve outcome for these children. Further validation 
on a larger prospective cohort will determine the effect of ALT and telomerase 
reactivation on the outcome of pediatric high grade gliomas and metastatic 
medulloblastomas. 
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CONCLUSION 
 
 
Our aim was to study specific molecular alterations involved in the processes of 
metastasis and cell survival in a series of 39 pediatric medulloblastomas with 
leptomeningeal dissemination at the onset. In fact, no gold standard treatment has been 
defined for metastatic MDB, and pediatric neuro-oncology research is focused on 
biomolecular characterization of these tumors, to treat patients with more appropriate 
therapies.  
First of all, we evaluated the prognostic relevance of the four molecular subgroups, with 
a sub-classification system widely available, in order to define risk classes for patients 
with leptomeningeal dissemination at diagnosis.  
Interestingly, the molecular features of medulloblastoma with metastasis at the onset are 
very similar compared to non-metastatic MDB. In fact, we showed that distribution of 
metastatic cases into four molecular subgroups, reflecting a high molecular 
heterogeneity, is highly similar to the frequency of non-metastatic ones. 
This work highlighted that our molecular subgrouping system could allow a risk 
stratification of metastatic medulloblastomas, to define high-risk patients (group SHH, 3 
and 4), with a survival rate <60%, and standard-risk patients (group WNT), with a 
survival rate >80%.  
In the future, we will extend the study of metastatic cohort under investigation to 
analyze the tumor cells genome methylation profiling, in order to classify samples that 
could not be attributed to any of subgroups basing on the markers so far analyzed. 
We also evidenced that FSTL5 over-expression was associated with poor outcome of 
patients, with survival rate <50%; FSTL5 gene expression can be used to better define 
outcome of patients with metastasis at the onset and to stratify these cases in different 
risk classes. The addition of FSTL5 expression analysis to existing molecular 
stratification schemes can constitute a reliable and cost-effective tool for prognostic 
evaluation in future clinical trials of metastatic MDB.  
Since FSTL5 is a glycoprotein which interacts with Ca2+ in extra-cellular space, we 
hypothesized that calcium dysregulation induced by FSTL5 over-expression can trigger 
to migration, invasiveness and malignancy of cells in high-risk subgroups of metastatic 
medulloblastomas.  
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Furthermore, we evaluated the possible activation of a pathway controlling elongation 
of telomeres, via the reactivation of telomerase or via ALT mechanism. 
Interestingly, we evidenced that medulloblastomas with metastasis at the onset control 
elongation of telomeres both via canonical pathway of telomerase reactivation and via 
ALT mechanism. ALT pathway is activated with higher frequency (27,3%) in our 
metastatic cases compared to non-metastatic MDB analyzed in literature (<5%), and is 
strongly associated with ATRX nuclear loss, while H3.3 mutations do not affect 
metastatic MDB. 
The observation that ALT is highly activated in our cohort highlights the biological 
differences between metastatic and non-metastatic medulloblastomas in control of 
telomere elongation, cells immortalization and senescence escape. 
Metastatic MDB have a higher activation of the canonical pathway of telomerase 
reactivation (13,6%) compared to pHGG (0%), induced by TERT promoter mutations in 
combination with UTSS hyper-methylation. UTSS hyper-methylation characterized our 
metastatic MDB with high incidence (59,5%) and could be associated with malignancy 
and invasiveness of these cases.  
Our findings suggest that immortalization of tumor cells in metastatic MDB is a 
common process to escape from the replicative senescence. 
Analysis of telomere elongation in medulloblastomas and other pediatric high-grade 
brain tumors via telomerase reactivation or ALT may contribute to risk stratification of 
patients and future development of targeted therapies. Further studies will be necessary 
to allow better classification and risk stratification, in order to identify aggressive 
tumors, requiring more invasive therapy, and patients with favorable prognosis, who 
might benefit from a reduction of chemotherapy and radiotherapy dosage.  
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